Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:39:08.067Z.
Calculation as of: 2026-10-06T22:39:08.067Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.06B
EV/EBIT Ratio
N/A
TTM Avg
4584.86x
3Y Avg
4584.86x
5Y Avg
4584.86x
Market Cap
$2.05B
EV/EBIT Ratio
110.67x
TTM Avg
307.23x
3Y Avg
485.43x
5Y Avg
1367.82x
Market Cap
$2.02B
EV/EBIT Ratio
N/A
TTM Avg
41.80x
3Y Avg
41.80x
5Y Avg
41.80x
Market Cap
$2.11B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
EV/EBIT Ratio
12.59x
TTM Avg
22.52x
3Y Avg
26.44x
5Y Avg
26.44x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 4584.86x | 4584.86x | 4584.86x |
| Alvotech (ALVO)vs › | $2.08B | 71.54x | 53.16x | 49.42x | 49.42x |
| Vericel Corporation (VCEL)vs › | $2.05B | 110.67x | 307.23x | 485.43x | 1367.82x |
| Progyny, Inc. (PGNY)vs › | $2.03B | 16.98x | 21.63x | 33.37x | 79.37x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 41.80x | 41.80x | 41.80x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 93.84x | 93.84x | 93.84x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 12.59x | 22.52x | 26.44x | 26.44x |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
